Area Drug and Therapeutics Committee Intravenous Acetylcysteine Prescribing and Administration Chart for patients ≥40kg*

Write or attach label
CHI No
Surname:
Forename: Sex:
DOB:



This chart is to be used when there has been determined a need to treat a paracetamol excess with acetylcysteine._To determine the need for acetylcysteine please consult TOXBASE[®] *If the patient is under 13 years of age but >40kg consider discussion with paediatrician

Date: Time: Allergies:

Date Time Allergies	
Total paracetamol ingested:g	For patients >110kg use 110kg to calculate toxic dose and acetylcysteine dose.
Calculated paracetamol ingested: mg/kg	For pregnant patients use pre-pregnancy weight to calculate toxic dose – and actual pregnant weight when prescribing acetylcysteine
Acetylcysteine Treatment Nomogram (for single overdose)	For all paracetamol overdose cases, when administration is required please
	use table 1 below.
110 0.7 -	
100 Treatment line - 0.7 Pasma-paracetamol concentration 90 0.6 - 0.5 - 0.5 80 - 0.5 - 0.4 - 0.3 70 - 0.3 - 0.3 - 0.1 90 - 0.3 - 0.1 - 0.1	 Note: Do not use the treatment nomogram to decide whether to treat if: timing of ingestion is unreliable there has been ingestion over a period of more than one hour – 'staggered overdose' there has been more than 24 hours lapsed since ingestion if there has been therapeutic excess
10 + + + + + + + + + + + + + + + + + + +	Please see specific guidance for these conditions on TOXBASE [®] www.toxbase.org (password required)

Table 1: Acetylcysteine intravenous dosing and administration

Regimen	First in	nfusion	Second infusion			
Infusion fluid	200mL 5% glucose or	sodium chloride 0.9%	1000mL 5% glucose or sodium chloride 0.9%			
Preparation	Use a 250mL infusion prior to adding in the acetylo	bag and remove 50mL e required volume of systeine	Add the required volume of acetylcysteine to the 1000mL infusion bag			
Duration of infusion	2 h	ours	10 h	ours		
Drug dose	100 mg/kg a	cetylcysteine	200 mg/kg a	cetylcysteine		
Patient weight (kg)	Ampoule volume (mL)	Infusion rate (mL/hour)	Ampoule volume ² (mL)	Infusion rate (mL/hour)		
40-49	23	112	45	105		
50-59	28	114	55	106		
60-69	33	117	65 107			
70-79	38	119	75	108		
80-89	43	122	85 109			
90-99	48	124	95 110			
100-109	53	127	105 111			
100 100						

Prescribe acetylcysteine on the inpatient patient prescription chart or Electronic Prescribing System 'Acetylcysteine as charted'.

Previous anaphylactoid reactions to acetylcysteine are **not** contraindications for a further treatment course. The 'SNAP' regimen does offer the benefit of lower rates of reactions than the previous regimen.

When IV treatment is not appropriate/possible please see TOXBASE® or contact the National Poisons Information Service, 0344 892 0111. Note TOXBASE contains information on giving acetylcysteine orally.

		nours											
Prescription						Prepara	ation	Administration checks					
								after 10 minutes and every hour					
Date	Time 00:00	Dose (mL) [#] See table 1	Diluent (200mL)	Infusion rate (mL/hour) See table	Prescribers signature	Prepare / Checł by	d by ked	Date/ remaini Time (mL)		ing infused) (mL)		Checked by	
				1		29							
Eac	h mL co	ntains 200	mg acetylo	cysteine									
nfus	sion	Acetvicy	steine 20	0 ma/ka o	ver 10	I F	Batch	n No – Ampo	ule(s):	E	Batch No –	diluent:	
2		hours						r					
		Pi	rescription			Prepara	ation	/ after	Administ	ratio	on checks	s bour	
-				Infusion				anei	Vol	.03 0	Vol	noui	
Date	Time 00:00	Dose (mL) [#] See table 1	Diluent (1000mL)	rate (mL/hour) See table 1	Prescribers signature	Prepare / Chec by	d by ked	Date/ Time	remainir (mL)	g	infused (mL)	Checked by	
Moni	toring F	Record											
Date :	sample	due											
l ime (2hrs b	sample	due sion end)											
Each	n mL cor	ntains 200	mg acetylc	vsteine									
			5										
								If no instruct	tion provic	ed to	continue o	r discontinue	
End trea	of tment	Take L end of	J&Es, bica infusion 2	arbonate, 2.	LFTs, FBC	, INR, ς	glucc	If no instruct in ose & Para	tion provic fusion – s acetam	ed to eek m	o continue o nedical revio evel 2 ho	r discontinue ew urs befor	
End trea	of tment	Take L end of Contin If any o rate us guidan	J&Es, bica infusion 2 ue treatm ALT abo ALT dou Paraceta criteria ab sed in the ce of whe	arbonate, 2. ent if AN ¹ ve the up bled or m amol conc ove are m 2nd treati en to disco	LFTs, FBC Y of the folk per limit no ore from ac entration > net; CONTI ment infusio ontinue trea	wing c rmal (U dmission 10mg/L NUE ex on and itment t	glucc rriteri LN) n (ev ktenc see	If no instruct in ose & Para a are met OR ven if norn ded treatm infusion 3 after.	ion provic fusion – s acetam : nal) OR nent at t advice	ed to eek m ol le	continue o nedical revie evel 2 ho dose and d TOXBA	r discontinu ew urs befor d infusior ASE® for	

Area Drug and Therapeutics Committee

Infusion device:

Infusion

Intravenous Acetylcysteine Prescribing and Administration Chart for patients ≥40kg

Acetylcysteine 100 mg/kg over 2

Serial/Equipment Number:

Write or attach label

CHI No

DOB:

Batch No - diluent:

Batch No – Ampoule(s):



Write or attach label CHI No

Surname:

Forename: Sex:

DOB:



Intravenous Acetylcysteine Prescribing and Administration Chart for patients ≥40kg

For Extended Treatment infusion 3

Infus 3	sion	Acetylc hours	ysteine 20) mg/kg oʻ	ver 10		Batch	n No – Ampo	ule(s):	Batch No – diluent:		
Prescription					Prepa	ration	Administration checks after 10 minutes and every hour					
Date	Time 00:00	Dose (mL) [#] See table 1	Diluent (1000mL)	Infusion rate (mL/hour) See table 1	Prescribers signature	Prepared by / Checked by		Date/ Time	Vol remainii (mL)	Vol ng infused (mL)	Checked by	
Moni	toring F	Record										
Date	sample	due										
Time (2hrs b	sample	due sion end)										
#Each	n mL cor	ntains 200)mg acetylc	ysteine								

If no instruction provided to continue or discontinue infusion – seek medical review

End of infusion 3	Take U&Es, bicarbonate, LFTs, FBC, INR, glucose, lactate (& Paracetamol level if >10mg/L after 2 nd infusion) 2 hours before end of infusion 3.
Extended treatment	 Continue treatment if ANY of the following criteria are met: ALT >2x upper limit normal (ULN) OR ALT >ULN and increased from previous AND doubled or more since admission OR Paracetamol level remains >10mg/L if checked OR INR >1.3 and increased from previous AND ALT >ULN If any criteria above are met; CONTINUE extended treatment at the dose and infusion rate used in the 2nd treatment infusion and see infusion 4 advice and TOXBASE® for guidance of when to discontinue treatment thereafter. Recheck U&Es, bicarbonate, LFTs, FBC and INR every 10 hours to assess course of liver injury. NOTE: If ALT is normal but INR has increased: Patients who do not meet any of the criteria for continuation of treatment but have an increase in INR of 0.4 or less and with a normal ALT can be considered for discharge. Patients who have an increase in INR of 0.5 more in the absence of an ALT rise, stop treatment and recheck INR and ALT after 4 - 6 hours. After this 4-6 hour period without treatment, consider discharge if the blood tests meet the following criteria: INR unchanged or falling AND ALT is less than two times the ULN. If criteria are not met – restart treatment at the dose and infusion rate used in the last treatment bag.

See over for infusion 4 onwards chart

Intravenous Acetylcysteine Prescribing and Administration Chart for patients ≥40kg

For Extended Treatment infusion 4 onwards

Write or attach label

CHI No Surname: Forename: Sex: DOB:



Infu	hfusion Acetylcysteine 200 mg/kg over 10 hours							n No – Ampoi	Batch No – diluent:		diluent:		
Prescription						Prepa	ration	Administration checks					
Date	Time 00:00	Dose (mL) [#] See table 1	Diluent (1000mL)	Infusion rate (mL/hour) See table 1	Prescribers signature	Prepared by / Checked by		Date/ Time	Vol remainir (mL)	ng	Vol infused (mL)	Checked by	
Moni	toring F	Record											
Date	sample	due											
Time sample due (2hrs before infusion end)													
#Eacl	h mL cor	ntains 200											
See g	guidance	e below r	egarding m	nanageme	nt at end of	infusi	on.						
												1	

If no instruction provided to continue or discontinue infusion - seek medical review

Infu	sion	Acetylc hours	ysteine 20	0 mg/kg o	ver 10		Batch	ch No – Ampoule(s):			Batch No – diluent:		
Prescription						Prepa	ration	Administration checks after 10 minutes and every hour					
Date	Time 00:00	Dose (mL) [#] See table 1	Diluent (1000mL)	Infusion rate (mL/hour) See table 1	Prescribers signature	Prepared by / Checked by		Date/ Time	Vol remainii (mL)	ng	Vol infused (mL)	Checked by	
Moni	toring F	Record					<u> </u>						
Date	Date sample due												
Time (2hrs b	sample before infu	due sion end)											
#Eac	n mL cor	ntains 200)mg acetylc	ysteine									

If no instruction provided to continue or discontinue infusion - seek medical review

End of infusion 4 onwards	Take U&Es, bicarbonate, LFTs, FBC, INR, glucose, lactate every 10 hours
Extended treatment	 Continue treatment UNTIL: INR 1.3 or less OR INR falling towards normal on 2 consecutive tests, and is <3.0 There is no advantage to treating ALT rises after normalisation of INR If treatment continues to bag 5 or more, extended treatment at the dose and infusion rate used in the 2nd treatment infusion and see TOXBASE[®] for guidance of when to discontinue treatment thereafter.